Skip to main
VANI

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical is positioned for potential growth due to the promising development of NPM-139, which has shown the ability to enhance the safety and tolerability of current treatments for chronic conditions, specifically targeting semaglutide therapies. The positive data indicating an approximate 20% weight loss sustained over six months suggests strong efficacy, which could enhance patient compliance and reduce therapy discontinuation rates. Furthermore, the advancements towards clinical development are supported by encouraging results, bolstering the company's prospects within both its Biopharm and Neuromodulation Divisions.

Bears say

Vivani Medical Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its lead candidate, NPM-139, in clinical trials. There are also concerns regarding NPM-139's ability to secure necessary regulatory approval and achieve commercial success, given uncertainties related to market size, penetration rates, and competition in the biopharmaceutical sector. Additionally, the company is exposed to dilution risk, which could further impact investor confidence and financial stability.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.